SageView Advisory Group
BIO icon

SageView Advisory Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

SageView Advisory Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73
Closed -$22.1K – 793
2025
Q4 		$22.1K Buy
+73
New +$22.8K ﹤0.01% 1409

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Ariel Investments
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SageView Advisory Group's BIO Position: Q1 2026 in Review

SageView Advisory Group sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 73 shares — an estimated $22.1K sold.

SageView Advisory Group first reported a position in BIO in Q4 2025 and held it in 1 quarter. The position peaked at $22.1K in Q4 2025. 395 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • SageView Advisory Group reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 73 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $22.1K.
  • SageView Advisory Group first reported a position in Bio-Rad Laboratories Class A in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Bio-Rad Laboratories Class A position peaked at $22.1K in Q4 2025.
  • 395 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.